NCT03442621 is a Phase 1 clinical trial of Relacorilant Fasted in Healthy, sponsored by Corcept Therapeutics.

Who is sponsoring NCT03442621?

NCT03442621 is sponsored by Corcept Therapeutics.

What drugs are being tested in NCT03442621?

Interventions in NCT03442621: Relacorilant Fasted, Relacorilant with a high fat breakfast, Relacorilant with a moderate breakfast.

What condition does NCT03442621 study?

NCT03442621 studies Healthy, Food-drug Interaction.

Is NCT03442621 still recruiting?

NCT03442621 is currently completed. Last updated 17 May 2018.

Last reviewed 2018-05-17 · How we verify

NCT03442621

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Relacorilant Food Effect Study in Healthy Subjects

Completed Phase 1 Last updated 17 May 2018

What this trial tests

Phase 1 trial testing Relacorilant Fasted in Healthy in 30 participants. Completed in 9 March 2018.

Timeline

16 January 2018

Primary endpoint
28 February 2018

9 March 2018

Quick facts

Lead sponsor	Corcept Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	30
Start date	16 January 2018
Primary completion	28 February 2018
Estimated completion	9 March 2018
Sites	1 location across United States

Drugs / interventions tested

Relacorilant Fasted — full drug profile →
Relacorilant with a high fat breakfast — full drug profile →
Relacorilant with a moderate breakfast — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →
Food-drug Interaction — all drugs for Food-drug Interaction →

Sponsor

Corcept Therapeutics — full company profile →

Who can join

Adults 18 to 65, any sex, with Healthy or Food-drug Interaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, randomized, single-dose, 3-period crossover, Williams' design, food-interaction (fasted and fed arms) study conducted in healthy subjects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.
Munster PN, Greenstein AE, Fleming GF, Borazanci E, et al · · 2022 · cited 25× · PMID 35583817 · DOI 10.1158/1078-0432.ccr-21-4363

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Corcept Therapeutics trials

Trials by the same sponsor.

NCT07240116 — Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects · Phase 1 · completed
NCT06829537 — Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM) · completed
NCT06928779 — Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant · Phase 1 · completed
NCT06495944 — Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants · Phase 1 · completed
NCT05772169 — Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifep · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03442621 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Corcept Therapeutics
Last refreshed: 17 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03442621.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing